Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-24

Clinical Trial Update: Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating teplizumab for recent-onset type 1 diabetes; study completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Teplizumab (Teplizumab)

Snippet

Sponsor: Provention Bio, Inc. | Conditions: Type 1 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2024-04-24